Furthermore, the potential beneficial effects of blocking the mTOR pathway with use of mTOR-inhibitors such as Metformin, Everolimus or Rapamycin (the latter not evaluated here) in COVID-19 patients hasbeen hypothesized, however its effects on gene expression and distinct signaling pathways remain to be satisfyingly established. This evidence concerns the gene MTOR and COVID-19.